Stock Track | Staar Surgical Soars 25.14% Intraday on Preliminary Q1 Sales Beat and Analyst Upgrades

Stock Track04-09

Staar Surgical's stock surged 25.14% during intraday trading on Thursday, following the company's announcement of preliminary first-quarter net sales that more than doubled year-over-year and significantly exceeded analyst expectations.

The implantable lens maker reported preliminary Q1 net sales above $90 million, compared to $42.6 million in the same period last year, representing growth of over 111%. This result substantially beat the consensus analyst estimate of approximately $67 million to $73 million. The company attributed the strong performance primarily to robust demand in China, its largest market, along with continued double-digit sales growth in the Americas.

Adding to the positive sentiment, Canaccord Genuity upgraded its rating on Staar Surgical to "Buy" from "Hold" and raised its price target to $27 from $22. Additionally, Wedbush increased its price target on the stock to $26 from $21. The company noted that the higher sales, combined with an improved cost structure, are expected to drive meaningful improvement in adjusted EBITDA for the quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105854044?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 22:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105854044","market":"sg","top_or_hot":-1,"title":"Stock Track | Staar Surgical Soars 25.14% Intraday on Preliminary Q1 Sales Beat and Analyst Upgrades","media":"Stock Track","content":"<p>Staar Surgical's stock surged 25.14% during intraday trading on Thursday, following the company's announcement of preliminary first-quarter net sales that more than doubled year-over-year and significantly exceeded analyst expectations.</p><p>The implantable lens maker reported preliminary Q1 net sales above $90 million, compared to $42.6 million in the same period last year, representing growth of over 111%. This result substantially beat the consensus analyst estimate of approximately $67 million to $73 million. The company attributed the strong performance primarily to robust demand in China, its largest market, along with continued double-digit sales growth in the Americas.</p><p>Adding to the positive sentiment, Canaccord Genuity upgraded its rating on Staar Surgical to \"Buy\" from \"Hold\" and raised its price target to $27 from $22. Additionally, Wedbush increased its price target on the stock to $26 from $21. The company noted that the higher sales, combined with an improved cost structure, are expected to drive meaningful improvement in adjusted EBITDA for the quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Staar Surgical Soars 25.14% Intraday on Preliminary Q1 Sales Beat and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Staar Surgical Soars 25.14% Intraday on Preliminary Q1 Sales Beat and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-09 22:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Staar Surgical's stock surged 25.14% during intraday trading on Thursday, following the company's announcement of preliminary first-quarter net sales that more than doubled year-over-year and significantly exceeded analyst expectations.</p><p>The implantable lens maker reported preliminary Q1 net sales above $90 million, compared to $42.6 million in the same period last year, representing growth of over 111%. This result substantially beat the consensus analyst estimate of approximately $67 million to $73 million. The company attributed the strong performance primarily to robust demand in China, its largest market, along with continued double-digit sales growth in the Americas.</p><p>Adding to the positive sentiment, Canaccord Genuity upgraded its rating on Staar Surgical to \"Buy\" from \"Hold\" and raised its price target to $27 from $22. Additionally, Wedbush increased its price target on the stock to $26 from $21. The company noted that the higher sales, combined with an improved cost structure, are expected to drive meaningful improvement in adjusted EBITDA for the quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STAA","symbol_name":"STAAR Surgical Company","start_time":0,"source_url":"","article_id":"1105854044","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105854044","pubTimestamp":1775744856,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Staar Surgical's stock surged 25.14% during intraday trading on Thursday, following the company's announcement of preliminary first-quarter net sales that more than doubled year-over-year and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STAA":"STAAR Surgical Company"},"translate_title":"个股追踪|Staar Surgical盘中大涨25.14%，因Q1销售初超预期及分析师上调评级","themeId":"40c55708269c8fdd426cc05dfae7d745","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STAA":1},"content_text":"Staar Surgical's stock surged 25.14% during intraday trading on Thursday, following the company's announcement of preliminary first-quarter net sales that more than doubled year-over-year and significantly exceeded analyst expectations.The implantable lens maker reported preliminary Q1 net sales above $90 million, compared to $42.6 million in the same period last year, representing growth of over 111%. This result substantially beat the consensus analyst estimate of approximately $67 million to $73 million. The company attributed the strong performance primarily to robust demand in China, its largest market, along with continued double-digit sales growth in the Americas.Adding to the positive sentiment, Canaccord Genuity upgraded its rating on Staar Surgical to \"Buy\" from \"Hold\" and raised its price target to $27 from $22. Additionally, Wedbush increased its price target on the stock to $26 from $21. The company noted that the higher sales, combined with an improved cost structure, are expected to drive meaningful improvement in adjusted EBITDA for the quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105854044","isCrawlerRequest":true}